Gerresheimer (XTRA:GXI) is back on investor radars after its Q3 2026 earnings call, which combined broad-based revenue growth, stable adjusted EBITDA and a confirmed full-year outlook with targeted portfolio sales to cut debt.
Gerresheimer’s recent Q3 update has arrived alongside a clear shift in market mood, with a 30 day share price return of 10.71% and a 90 day gain of 16.34%. This suggests momentum is rebuilding after a three year total shareholder return decline of 63.85%.
Scan other potential rebound stories alongside Gerresheimer by checking out our curated list of 603 high quality undiscovered gems that the market may not be fully pricing in yet.
Gerresheimer now appears to be a solid operator working to repair a bruised share price. After a sharp short-term rebound, is this still a value opportunity, or has the recovery already been fully priced in?
Most Popular Narrative: 17% Overvalued
Gerresheimer last closed at €32.04 while the most followed narrative anchors fair value at €27.38. The current rebound sits above that reference point and puts more pressure on execution of the turnaround story.
The planned sale of Centor and Primary Packaging Plastics for about €1.5b enterprise value and the aim to refinance all group debt once both deals close could leave Gerresheimer trading as if a lower net debt to EBITDA ratio and improved interest expense are already secured, which could overstate sustainable earnings power.
See why 14 investors see Gerresheimer as 17% overvalued.
Result: Fair Value of €27.38 (OVERVALUED)
Still, if Gerresheimer executes the €1.5b disposals cleanly and the Bormioli Pharma integration progresses smoothly, the current overvaluation narrative could be challenged quickly.
Find out about the key risks to this Gerresheimer narrative.
Another View: Gerresheimer Looks Cheap On Sales
The fair value anchor of €27.38 paints Gerresheimer as overvalued, yet its P/S of 0.5x is far below the European Life Sciences average of 3.8x, the peer average of 3x and even a fair ratio estimate of 0.8x. That kind of gap lowers the margin for error but also raises a question about how much downside is already in the price.
For a closer look at what the numbers imply across these sales multiples, and how much room there might be for sentiment to shift toward that fair ratio, See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Feeling mixed on Gerresheimer so far, or starting to lean one way? Act while the facts are fresh and review the full picture for yourself with 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Gerresheimer?
If Gerresheimer has you rethinking where value might be hiding, do not stop here. Fresh ideas often come from comparing stories side by side.
- Target high quality companies trading below what their fundamentals suggest with our hand picked set of 199 high quality undervalued stocks that might be flying under the radar.
- Prioritise resilience and sleep easier at night by scanning a 218 resilient stocks with low risk scores built to spotlight businesses with sturdier risk profiles.
- Strengthen your shortlist with a list of solid balance sheet and fundamentals (203 results) that highlights companies combining sound finances with underlying business fundamentals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com